ADMA Biologics Inc — Balance Sheet (NASDAQ:ADMA) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Total assets 207.67 M276.25 M348.46 M329.18 M488.68 M624.24 M Total liabilities 119.42 M135.08 M196.49 M193.98 M139.66 M146.92 M Total equity 88.25 M141.17 M151.97 M135.21 M349.02 M477.32 M Total liabilities & shareholders' equities 207.67 M276.25 M348.46 M329.18 M488.68 M624.24 M Total debt 92.97 M94.87 M142.83 M130.59 M72.34 M72.14 M Net debt -44.19 M-48.76 M-87.73 M-45.98 M-97.25 M-11.65 M

Haberler

Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes

Is ADMA Poised for Margin Growth and Supply Expansion in 2026?

Adma Biologics (ADMA) Laps the Stock Market: Here's Why

ADMA Biologics: The Short Report Is The Noise, Not The Signal (NASDAQ:ADMA)

Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?

NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up

Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio

Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study

ADMA Biologics: Differentiated Plasma Approach With Asymmetric Upside Potential (Upgrade)

Novartis Bolsters Immunology Pipeline With Excellergy Deal

Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes

KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate